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Background: Assaying for the parasitic lactate dehydrogenase (pLDH) is widely used as a rapid diagnostic test
(RDT), but the efficacy of its serological effectiveness in diagnosis, that is antibody detection ability, is not known.
The genetic variation of Korean isolates was analysed, and recombinant protein pLDH was evaluated as a
serodiagnostic antigen for the detection of Plasmodium vivax malaria.
Methods: Genomic DNA was purified, and the pLDH gene of P. vivax was amplified from blood samples from 20
patients. The samples came from five epidemic areas: Bucheon-si, Gimpo-si, and Paju-si of Gyeonggi Province,
Gangwha-gun of Incheon metropolitan city, and Cheorwon-gun of Gangwon Province, South Korea, from 2010 to
2011. The antigenicity of the recombinant protein pLDH was tested by western blot and enzyme-linked
immunosorbent assay (ELISA).
Results: Sequence analysis of 20 Korean isolates of P. vivax showed that the open reading frame (ORF) of 951
nucleotides encoded a deduced protein of 316 amino acids (aa). This ORF showed 100% identity with the P. vivax
Belem strain (DQ060151) and P. vivax Hainan strain (FJ527750), 89.6% homology with Plasmodium falciparum
FCC1_HN (DQ825436), 90.2% homology with Plasmodium berghei (AY437808), 96.8% homology with Plasmodium
knowlesi (JF958130), and 90.2% homology with Plasmodium reichenowi (AB122147). A single-nucleotide
polymorphism (SNP) at nucleotide 456 (T to C) was also observed in the isolate from Bucheon, but it did not
change in the amino acid sequence. The expressed recombinant protein had a molecular weight of approximately
32 kDa, as analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. Of the 40
P. vivax patients, 34 (85.0%) were positive by ELISA.
Conclusions: The pLDH genes of 19 isolates of P. vivax were identical, except one for SNP at nucleotide 456. This
observation indicates that this gene is relatively stable. Based on these results, the relationship between antibody
production against pLDH and the pattern of disease onset should be investigated further before using pLDH for
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Global figures for deaths caused by malaria range from 1.5
to 2.7 million each year, most of which are children under
five years of age and pregnant women. Most of the deaths
are caused by Plasmodium falciparum [1,2]. The clinical
diagnosis of malaria still relies upon the identification of
malaria parasites in Giemsa-stained blood smears of
peripheral blood. Therefore, microscopic observation
of the Plasmodium species is regarded as the “gold
standard” for malaria diagnosis. Despite the simplicity and
low cost, such a diagnostic technique is not always available
[3]. Rapid diagnostic tests (RDTs) have been introduced to
overcome time constraints, a lack of trained personnel in
remote or isolated areas, and the low sensitivity when diag-
nosing malaria infections with a low level of parasitaemia
[4]. These lateral-flow immunochromatographic tests
detect specific antigens that are produced by malaria
parasites and are rapid and simple to carry out without
electricity, specific equipment or intensive training [5-8].
To detect Plasmodium, monoclonal antibodies against
parasite lactate dehydrogenase (pLDH), histidine-rich
protein-2 (HRP-2), and aldolase are widely used. The
genetic diversity of HRP-2 is known to partly influence the
sensitivity of RDT. pLDH catalyzes the inter-conversion of
lactate into pyruvate. Therefore, this enzyme is essential for
energy production in Plasmodium species. The level
of pLDH in the blood has been directly linked to
the level of parasitaemia [9-12]. pLDH (L-lactate:
NAD + −oxidoreductase, EC 1.1.1.27) is the one of the
first malaria parasite enzymes that was shown to be electro-
phoretically and kinetically distinct from a human enzyme
[13,14]. Glucose utilization in P. falciparum-infected
erythrocytes is as much as 100 times the rate observed in
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Figure 1 A) The conformation of cloned pCR-pLDH containing the pL
non-inserted clone; lane 2, pLDH gene inserted clone (pVpLDH). B) Confirm
digestion with EcoRI and HindIII. M, Molecular size marker; lane 1, Undigest
digested plasmid.role in regulating glycolysis and in balancing the
reduced/oxidized state of the malaria parasites [16,17].
Using RDTs of monoclonal antibodies against the pLDH
antigen, sensitivity was over 90%, with high parasite
density of P. falciparum. However, the sensitivity
decreased to under 70% in parasitaemia of less than
50 parasites/μl [6,18,19].
The creation of diagnostic tools and methods for
asymptomatic and low parasitaemia patients has been
attempted by the malaria team of the Korean National
Institute of Health (KNIH). To accomplish this task,
genetic variations of P. vivax pLDH were investigated to
identify the typical strain of Korean isolates, and its
recombinant protein was evaluated as an antibody
detection tool whether it could compensate for the missing
cases by antigen detection with RDTs which showing
low antigen detection ability in low parasite density.Methods
Blood sample collection
Patients with clinically suspected malaria attending
the Public Health Centers in Gangwha-gun, Gimpo-si,
Bucheon-si, and Paju-si of Gyeonggi Province and
Cheorwon-gun of Gangwon Province, South Korea
from 2010 to 2011 were examined for malaria para-
sites. Approximately 3 ml of blood was collected from
each symptomatic patient. Thin and thick blood
smears were prepared for microscopic examination.
Blood samples were transported to the Korean Na-
tional Institute of Health (KNIH), where sera were
separated and stored at −20°C for future analysis. In-
formed consent was obtained from all patients, and
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DH gene by digestion with EcoRI. M, Molecular size marker; lane 1,
ation of pLDH gene in Eschelichia coli DH5α by restriction enzyme
ed Plasmid; lane 2, BamHI digested Plasmid; lane 3, EcoRI and HindIII
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Figure 2 Comparing the single-nucleotide polymorphism (SNP) of the pLDH gene among 20 Plasmodium vivax Korean isolates. All
amino acid sequences were deposited in GenBank (http://WWW.ncbi.nlm.nih.gov/nuccore, Accession No. JX865768-JX865780, JX872274-JX872280).
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Ethics Committee of the National Institute of Health
(Osong, Korea).
Amplification of pLDH
For the purpose of the expression of the pLDH gene,
genomic DNA was extracted from the whole blood of a
malaria patient using a QIAamp Blood Kit (Qiagen,
Hilden, Germany). PCRs were performed using
AccuPower PCR Premix (Bioneer, Taejeon, Korea), 50 ng
of purified genomic DNA, and 40 pmoles each of for-
ward (pLDH-F1; 5′-GGA TCC GCT ACT CAG AGG
GAG GTG CTC GTC GAA ATC-3′) and reverse
primers (pLDH-R1; 5′-GCA TGC GAG GCA GTA CTC
TCC GCA GTC CGG ATC AGT-3′), and the total vol-
ume was adjusted to 20 ml with distilled water. The
thermocycler conditions were as follows: denaturation at
94°C for 5 min; 35 cycles of 1 min at 94°C, 1 min at
58°C and 2 min at 72°C; and incubation at 72°C for
5 min. All of the PCR products were analysed on a 1.0%
agarose gel, confirmed under a UV transilluminator andNucleotide Substitutions (x100)
0.1
Figure 3 Nucleotide sequence differences in pLDH genes from Plasm
Korean isolates were aligned. Computer analysis was performed using the
sequences were deposited in GenBank BLAST (http://WWW.ncbi.nlm.nih.gopurified with a Qiagen plasmid mini kit (Qiagen). The
purified PCR products were ligated into a pCR2.1 clon-
ing vector (Invitrogen, Carlsbad, CA, USA) and then
transformed into Escherichia coli Top10 according to
Invitrogen’s procedures.
DNA sequencing and analysis
The PCR product inserted into E. coli Top10 was se-
lected for on ampicillin- and 5-bromo-4-chloro-indolyl-
β-D-galactopyranoside (X-gal)-containing medium. To
confirm transformants, gel electrophoresis was performed
after EcoRI digestion (Figure 1A) of a plasmid prepared
with a Qiagen plasmid mini kit, according to the protocol
supplied by the manufacturer. The pLDH gene sequence
was determined using an ABI PRISM dye terminator cycle
sequencing ready reaction kit FS (Perkin Elmer,
Cambridge, MA, USA) according to the supplied manual.
M13 reverse and M13 forward (−20) primers were used in
sequencing. Nucleotide and deduced amino acid se-
quences were analysed using EditSeq and Clustal in the





















odium vivax Korean isolates. The nucleotide sequences of 20 P. vivax
multiple sequences alignment tool of MegAlign. All nucleotide
v/nuccore, Accession No. JX865768-JX865780, JX872274-JX872280).
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Figure 4 Multiple amino acid sequence alignment of pLDH among Plasmodium species. The deduced amino acid sequence of the
PvKtype19 type strain in P. vivax Korean isolates was aligned with those from other Plasmodium species. Computer analysis was performed using the
multiple sequences alignment of MegAlign. All amino acid sequences were obtained from GenBank BLAST (http://WWW.ncbi.nlm.nih.gov/nuccore).
Pv Belem (P. vivax, Accession; DQ060151), Pf FCC1_HN (P. falciparum, DQ825436), Pf Mzr-1 (P. falciparum, JN54719), Pf Ori-1 (P. falciparum, JN547218),
Pb (P. berghei, AY437808), Pk (P. knowlesi strain H, JF958130), and Pr (P. reichenowi, AB122147).
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The internet-based BLAST search program of the Na-
tional Center for Biotechnology Information (NCBI) was
used to search protein databases. The gene sequences of
pLDH from the Korean isolates were deposited in
GenBank (Accession No. JX865768-JX865780, JX872274-
JX872280).
Construction of the pLDH expression vector
For the expression of the pLDH gene of the PvKtype19
type strain in E. coli, the gene fragment was amplified
from the DNA of blood samples that were confirmed to
be infected with P. vivax as described above and which
had BamHI and SphI sites on their 5’ ends. Amplified
PCR products were digested with BamHI and SphI, puri-
fied with a Qiagen Gel Extraction Kit after running on
an agarose gel and integrated into the BamHI and SphINucleotide Substitutions (x1
5.5
4
Figure 5 Amino acid sequence differences in pLDH among Plasmodiu
strain in P. vivax Korean isolates was aligned with those from other Plasmo
sequences alignment tool of MegAlign. All amino acid sequences were ob
Pv Belem (P. vivax, Accession; DQ060151), Pf FCC1_HN (P. falciparum, DQ82
JN547218), Pb (P. berghei, AY437808), Pk (P. knowlesi strain H, JF958130), ancleavage sites of a pQE80 expression vector (Qiagen).
The resulting plasmid was subsequently used for the ex-
pression of the pLDH recombinant protein in E. coli
DH5α. Transformants were confirmed by gel electro-
phoresis of plasmid DNA after restriction enzyme diges-
tion with EcoRI and HindIII (Figure 1B).
Expression and purification of recombinant pLDH protein
Expression of the pLDH recombinant protein was induced
in E. coli with isopropyl-1-thio-β-D-galactopyranoside
(IPTG). A total of 1 mM IPTG was added to cultures of E.
coli DH5α (pVKtype19) grown to the logarithmic phase in
liquid Luria Betani (LB) medium containing 100 μg/ml
ampicillin to induce expression of the target protein. Puri-
fication of pLDH recombinant protein was carried out
using immobilized metal ion affinity chromatography [20].
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Figure 6 Multiple amino acid sequence alignment of pLDH among Plasmodium vivax. The deduced amino acid sequence of the PvKtype19
type strain in P. vivax Korean isolates was aligned with those from other Plasmodium species. Computer analysis was performed using the multiple
sequences alignment tool of MegAlign. All amino acid sequences were obtained from GenBank BLAST (http://WWW.ncbi.nlm.nih.gov/nuccore).
PvKtype19 (Korean type strain), PvKvar (Variant form of Korean isolate), Pv Belem (P. vivax, Accession; DQ060151), and Pv Hainan (P. vivax, FJ527750).
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Proteins were analysed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) after each
purification step.
Western blot analysis
Recombinant pLDH protein was separated on a 12%
SDS-PAGE gel and was then transferred to a nitrocellu-
lose membrane. After the transfer, the membrane was
cut into strips and blocked for nonspecific binding with
5% skim milk for 12 hours at 4°C. The membrane was
then washed in PBS with 0.15% Tween 20 for 3 ×
10 min. The strips were allowed to react with the sera
from malaria patients or from uninfected people (diluted
1:100, vol/vol) for four hours and then washed using
the procedure described above. The membrane was
subsequently incubated with diluted peroxidase-conjugated
goat anti-human IgG secondary antibody (1:1,000, v/v)
(Sigma) for three hours at room temperature. For colourNucleotide Substitutions (x
1.3
Figure 7 Phylogenetic relationships among the pLDH of several strain
multiple sequences alignment tool of MegAlign. All amino acid sequences wer
PvKtype19 (Korean type strain), PvKvar (Variant form of Korean isolate), Pv Belem
(P. vivax, JN547221), Krt-1 (P. vivax, JN547225), and Goa-1 (P. vivax, JN547223).development, a solution containing 0.2% diaminobenzidine
and 0.02% H2O2/PBS was applied to each well [21].
Enzyme-linked immunosorbent assay
Sera from patients infected with P. vivax were analysed for
the presence of antigen-specific antibodies using 96-well
plates coated with 0.5 mg/ml purified recombinant protein
that had been expressed in E. coli and dissolved in
phosphate-buffered saline (PBS, pH 7.4) overnight at 4°C.
Malaria patient serum was diluted 1:100 (v/v) in blocking
buffer (0.25% PBS-Tween 20 with 1% bovine serum albu-
min, pH 7.4) and incubated for one hour, followed by incu-
bation with peroxidase-conjugated goat anti-human IgG
secondary antibody at a 1:1,000 dilution (v/v, Sigma). Op-
tical density was measured with a spectrophotometer at
405 nm (Molecular Devices, Sunnyvale, CA, USA) [22].
Samples were regarded as positive when sera were over the
cut-off value, which was calculated as the mean + 2 X the









s of Plasmodium vivax. Computer analysis was performed using the
e obtained from GenBank BLAST (http://WWW.ncbi.nlm.nih.gov/nuccore).
(P. vivax, Accession; DQ060151), Pv Hainan (P. vivax, FJ527750), Ori-1
Figure 8 A) Purification of pLDH with Ni-NTA agarose affinity chromatography. Lane M, molecular weight protein marker; lane 1, induced
E. coli DH5α cell lysate with IPTG; lane 2, flow-through; lane 3, wash; lane 4–5, elutes. B) Western blot analysis of pLDH recombinant protein. a,
Malaria patients; b, Healthy individuals. C) Scattergram of absorbances measured by ELISA using pLDH recombinant protein. Sera from healthy
individuals and malaria patients infected with P. vivax were used. Cut off showed the mean + 2 X SD of negative controls.
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Sequence variation of pLDH genes from Plasmodium
vivax Korean isolates
The geographical locations of blood sample collection
were Gangwha (37.31 N 125.33E) of the Incheon metro-
politan city, Gimpo-si (37.33 N 126.48E), Bucheon
(37.29 N 126.46E), Paju (37.88 N 126.76E) of Gyeonggi
Province, and Cheorwon (38.10 N 127.30E) of Gangwon
Province. Four blood samples infected with indigenous
P. vivax were collected from each city during 2010–
2011. The pLDH gene was amplified from the genomic
DNA of 20 P. vivax Korean isolates. Amplification of the
pLDH gene yielded a product of approximately 950 base
pairs. After purification, the DNA fragment was ligated
into the pCR 2.1 cloning vector (3.9 kb). The plasmid
containing the PCR product was named pVpLDH
(5.0 kb) and was used for DNA sequence analysis
(Figure 1). Based on DNA sequencing, the cloned pLDH
gene was 951 bp and consisted of 316 amino acids that
were deduced by DNASIS. One single-nucleotide poly-
morphism (SNP) was detected at base pair 456 (n = 1),
from T to C, in the Bucheon 3 isolate (isolated on Sep.
14th 2010) designated as PvKvar (Figures 2 and 3), but it
did not change in the amino acid sequence. Therefore, of
the 20 Korean isolates of pLDH, 19 isolates had the same
DNA and amino acid sequences as P. vivax Belem
(DQ060151). These isolates were designated as type strain
PvKtype19. When the amino acid sequence of PvKtype19
was compared with several Plasmodium species, PvKtype19
showed 89.5% identity with P. falciparum FCC1_HN(DQ825436), 90.2% with P. falciparum Mzr-1 (JN54719),
90.2% with P. falciparum Ori-1 (JN547218), 90.2% with
P. berghei (AY437808), 96.8% with Plasmodium knowlesi
(JF958130), and 90.2% with Plasmodium reichenowi
(AB122147) (Figures 4 and 5). When the amino acid se-
quence of PvKtype19 was compared with several P. vivax
strains, PvKtype19 showed 100% identity with P. vivax
Hainan (FJ527750), 97.8% with P. vivax Ori-1 (JN547221),
99.7% with P. vivax Krt-1 (JN547225), and 98.4% with
P. vivax Goa-1 (JN547223) (Figures 6 and 7).Expression of pLDH in Escherichia coli
The resulting plasmid pVKtype19 contained a pLDH
gene fused to a (His) 6-tag based on pQE80 (Figure 1B).
The recombinant plasmid pVKtype19 was then trans-
ferred into E. coli DH5α. As analysed by SDS-PAGE
followed by Coomassie blue staining, the pLDH recom-
binant protein was 32 kDa under native purification
conditions (Figure 8A).Antigenicity of the pLDH recombinant protein
To determine the antigenicity of the pLDH recombinant
protein by western blot and ELISA, the sera of malaria
patients that had been collected between 2009 and 2010,
which confirmed by microscopic examination but did
not count the parasites (parasitaemia), and kept by the
KNIH were analysed. Negative sera were collected from
staff volunteers from the KNIH.
Shin et al. Malaria Journal 2013, 12:166 Page 7 of 8
http://www.malariajournal.com/content/12/1/166The sera of six of nine malaria patients exhibited a
positive reaction by western blot, while the sera from the
normal control group (n = 7), who had never been ex-
posed to malaria, tested negative (Figure 8B). After the
number of malaria patients was increased, the antigenic-
ity of the recombinant pLDH protein was evaluated by
ELISA. Thirty-four of the 40 sera (85.0%) from malaria
patients, as confirmed by microscopic analysis, reacted
with the pLDH recombinant protein. In addition, all of
the 26 samples from the normal control group failed to
react with the pLDH recombinant protein (Figure 8C).
Discussion
pLDH is one of the target antigens that is widely used
in developing the monoclonal antibodies that are part
of the RDT that comprises the non-microscopic
immunochromatographic assay. Interestingly, the level
of pLDH has been shown to decline in parallel with the
clearance of asexual parasitaemia; therefore, it has been
suggested that the disappearance of the parasite-specific
enzyme pLDH after anti-malarial drugs may be useful in
predicting treatment failure [23]. These characteristics of
pLDH led us to investigate the sequence variability of
pLDH in Korean isolates. PvKtype19, which was the pre-
dominant form of pLDH in Korean isolates, exhibited
higher identity with P. knowlesi (96.8%, JF958130) than
with P. falciparum Ori-1 (JN547218) (Figures 4 and 5).
However, PvKtype19 showed 97.8-100% identity with
other subspecies of P. vivax (Figures 6 and 7). Only one
synonymous SNP was found in 20 Korean isolates, at
base pair 456 (n = 1) (Figures 2 and 3).
Plasmodium vivax has presumably been prevalent in
Korea for a long time. However, as a result of a national
malaria eradication programme and with help from the
World Health Organization (WHO), the incidence of vivax
malaria has rapidly decreased [24,25]. After the latest report
of two malaria patients in 1985 [26], there were no add-
itional reported cases until one case was reported in 1993
[27] and two indigenous cases were reported in 1994 [28].
Malaria cases then rapidly increased until approximately
2000 [29,30]. After that, the reported malaria cases de-
creased for several years due to efforts to limit the incidence
of malaria. However, malaria has not been thoroughly eradi-
cated in the Korean peninsula because 2 to 3% of patients
experience failed drug treatment every year, and many trav-
ellers and workers come from malaria-prevalent areas, in-
cluding North Korea [31]. For these reasons, serological
diagnostic tools are needed to support both traditional
microscopic diagnosis and antibody testing on a population
level, to get a proxy about exposure to malaria in Korea.
Currently, IFAT (Immunofluorescence antibody test) is
used as the standard serological diagnostic method due to
its high sensitivity in this context. However, the sensitivity
might be affected by the training and ability of examiners.Therefore, a new antigen is needed for serodiagnosis. Sev-
eral recombinant proteins cloned from Korean isolates of P.
vivax have been tested for use as antigens for serodiagnosis,
including circumsporozoite protein (CSP), subtypes Pv210
[32] and Pv247 [33], merozoite surface protein (MSP) [34],
and CSP and MSP chimeric proteins [35,36]. None of these
antigens were capable of replacing the IFAT method be-
cause their sensitivity was less than that of IFAT. Therefore,
it was decided to focus on pLDH. Monoclonal antibodies
against pLDH have been used in several RDTs and exhibit a
relatively high sensitivity for the detection of malaria para-
sites. However, the ELISA detected only 85.0% (34/40) of
microscopic positive samples, even though it was cloned
from a Korean vivax malaria strain (pVKtype19, Figure 5).
Therefore, antibody detection using the pLDH recombinant
protein is not sufficient to compensate the disadvantage of
antigen detection using its monoclonal antibody. However,
it should be investigated whether pLDH recombinant pro-
tein can detect asymptomatic patients or symptomatic pa-
tients who have low parasitaemia (under 50/μl) using by
antibody detection methods, for example, ELISA or West-
ern blot. Therefore, when using the RDT in the field, it is
likely better to use both antigen and antibody detection
RDTs to compensate for their individual limitation.
Conclusions
The pLDH gene from P. vivax Korean isolates has an
SNP at position 456 (T to C). New information from the
geographic mapping of pLDH at the national or regional
scale would provide a valuable aid for developing and
updating the national anti-malarial policy guidelines in
Korea. Additionally, more information is needed before
using pLDH as a serological diagnostic antigen.
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